ONO-4059 Study in Patients With Steroid-resistant Pemphigus

ONO-4059-10:Multicenter, Placebo-controlled, Randomized, Double-blind, Phase 3 Study in Patients With Steroid-resistant Pemphigus (BRILLIANT Study)

ONO-4059-10:Multicenter, placebo-controlled, randomized, double-blind, Phase 3 study in patients with steroid-resistant pemphigus

Inclusion Criteria:

• Patients with a diagnosis of pemphigus
• Patients with a re-increase in the pemphigus disease area index (PDAI) score before oral corticosteroid tapering to 10mg/day of prednisolone (PSL) equivalent

Exclusion Criteria:

• Patients with an active infection
• Patients with malignancy
• Patients with past history of serious allergy or anaphylaxis